EW$81.34

Edwards Lifesciences Corporation exhibits mixed growth trends. Revenue has generally grown, with TTM revenue of $6,304 million exceeding FY2025's $6,068 million, suggesting recent momentum. However, net income growth has been highly volatile, with a significant spike in FY2024 due to discontinued operations, followed by a sharp decline. Gross margins are strong, consistently above 75%, but operating margins have compressed from 32.3% in FY2021 to 20.84% in FY2025, indicating rising operating expenses relative to revenue. The FY2024 net income surge was primarily driven by a large gain from discontinued operations ($2,774 million), which is a one-time event and not indicative of structural earnings power. Assuming EW operates in the medical device sector, its gross margins are excellent, but the declining operating margin and volatile net income are concerning. Risks include the sustained increase in total operating expenses outpacing revenue growth, leading to operating margin compression, and the reliance on one-off gains for significant net income boosts, masking underlying profitability challenges.

Edwards Lifesciences demonstrates a robust balance sheet, characterized by strong liquidity and a healthy capital structure. Cash and short-term investments have shown significant growth, reaching $4,226 million in FY2025, providing ample liquidity. Total current assets consistently exceed total current liabilities, with current assets at $6,739 million and current liabilities at $1,814 million in FY2025, indicating strong working capital. Solvency is excellent, with total liabilities at $3,360 million against total assets of $13,697 million in FY2025, and a low long-term debt of $598.3 million. Shareholders' equity has steadily increased, reaching $10,338 million in FY2025, reflecting consistent retained earnings growth. The company's net cash position has also grown substantially, reaching $3,521 million in FY2025, further reinforcing its financial strength and flexibility.

Edwards Lifesciences' operating cash flow (OCF) has shown significant volatility, with a sharp decline from $1,732 million in FY 2021 to $542.3 million in FY 2024, before a strong rebound to $1,595 million in FY 2025 and a TTM of $1,359 million. This inconsistency, particularly the large drop in FY 2024, raises some concerns about the stability of cash generation. Free cash flow (FCF) mirrors this trend, falling to $289.9 million in FY 2024 before recovering to $1,335 million in FY 2025. Capital expenditures have been relatively stable, indicating consistent reinvestment. However, the substantial swings in investing activities, driven by large purchases and proceeds from investments, and significant share repurchases in financing activities, suggest a dynamic capital allocation strategy that warrants close monitoring.

Edwards Lifesciences demonstrates strong liquidity, with its Quick Ratio improving from 2.07 to 3.3 and Current Ratio from 3.08 to 4.42 over the period, indicating a robust ability to meet short-term obligations. Leverage remains very manageable, as evidenced by a consistently low Debt/Equity Ratio, which has decreased from 0.11 to 0.07, and a negative Net Debt/Equity, suggesting a net cash position. Efficiency metrics show some variability; Asset Turnover has slightly declined from 0.66 to 0.47, while Inventory Turnover has improved from 0.9 to 1.24 since FY2022. Profitability and returns, while still healthy, have seen a downward trend, with ROE decreasing from 28.88% to 10.39% and ROIC from 27.15% to 13.97%. Despite this, the company maintains solid returns on capital.

Edwards Lifesciences Corporation shows a mixed growth trajectory. Historically, revenue growth fluctuated significantly, with a notable -14.69% contraction in FY 2022 followed by a recovery. Analyst estimates project a more stable, albeit moderate, revenue growth in the 8.57% to 14.44% range through FY 2027. EPS growth has been highly volatile, with a substantial 202.39% spike in FY 2024 followed by a sharp -73.7% decline in FY 2025, before recovering. This volatility suggests potential margin pressures or one-off events impacting earnings. Forward P/E ratios for FY 2026 (26.48) and FY 2027 (23.66) appear reasonable given the projected growth rates. Analyst sentiment is generally positive, with a 'Buy' consensus rating from 19 analysts and a stable recommendation trend showing consistent 'Strong Buy' and 'Buy' ratings over recent months. The price target range indicates a degree of confidence, with an average target of $96.37.